1. Home
  2. TNET vs NTLA Comparison

TNET vs NTLA Comparison

Compare TNET & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriNet Group Inc.

TNET

TriNet Group Inc.

N/A

Current Price

$36.12

Market Cap

1.6B

ML Signal

N/A

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

N/A

Current Price

$12.86

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TNET
NTLA
Founded
1988
2014
Country
United States
United States
Employees
2700
N/A
Industry
Business Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2000
2016

Fundamental Metrics

Financial Performance
Metric
TNET
NTLA
Price
$36.12
$12.86
Analyst Decision
Hold
Buy
Analyst Count
6
20
Target Price
$65.80
$20.45
AVG Volume (30 Days)
692.0K
3.6M
Earning Date
05-15-2026
05-21-2026
Dividend Yield
3.04%
N/A
EPS Growth
N/A
27.43
EPS
3.20
N/A
Revenue
$5,010,000,000.00
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.30
$73.07
P/E Ratio
$11.31
N/A
Revenue Growth
N/A
16.92
52 Week Low
$33.67
$5.90
52 Week High
$88.56
$28.24

Technical Indicators

Market Signals
Indicator
TNET
NTLA
Relative Strength Index (RSI) 33.00 47.69
Support Level $33.67 $10.44
Resistance Level $63.28 $15.06
Average True Range (ATR) 1.97 0.95
MACD 0.57 -0.12
Stochastic Oscillator 43.37 12.08

Price Performance

Historical Comparison
TNET
NTLA

About TNET TriNet Group Inc.

Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company providesits services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: